2. QUALITATIVE AND QUANTITATIVE COMPOSITION

ADVANTAN Presentation Uses - Medsafe

ADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.

  Presentation, Advantan presentation uses, Advantan, Uses, Methylprednisolone aceponate, Methylprednisolone, Aceponate

LOXALATE 1. Product Name - Medsafe Home Page

Page 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.

  Risks, Combination

DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …

New Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …

  Sheet, Data, Data sheet, Clexane

SEPTANEST Articaine hydrochloride 4% with …

SEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.

  Articaine

BOOSTRIX - Medsafe Home Page

1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.

  Information, Boostrix

NEW ZEALAND DATA SHEET - Medsafe

NEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a

  Cymevene

Edition Draft - Medsafe

Part 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for

  Draft, Good, Practices, Manufacturing, Edition, Edition draft, Good manufacturing practice

Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …

New Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …

  Product, Name, Sheet, Data, Data sheet 1 product name

NEW ZEALAND DATA SHEET MESTINON® - Medsafe

NEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to

  Myasthenia, Gravis, Myasthenia gravis, Mestinon

DATA SHEET PREDNISONE - Medsafe

• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since

  Myasthenia, Gravis, Myasthenia gravis, Prednisone

Guidelines for the management of cutaneous warts

British Journal of Dermatology 2001; 144: 4–11. Guidelines for the management of cutaneous warts J.C.STERLING,* S.HANDFIELD-JONES,† P.M.HUDSON‡

  Management, For the management

PHARMACY UPDATE Antihistamine use in children

Table 1 Summary of the more commonly used H(1)-antihistamines licensed for use in children First-generation H(1)-antihistamines The most common adverse effect of the first-generation H(1)-antihistamines is central nervous system depression, with effects varying from slight drowsiness to …

  Update, Pharmacy, Children, Pharmacy update antihistamine use in children, Antihistamine

CONTINUING EDUCATION AND TRAINING Gain 2 CET …

CONTINUING EDUCATION AND TRAINING Gain 2 CET credits – enter online at www.otcet.co.uk or by post pared to white patients.9 A relatively high incidence has been documented in the

Emollient Prescribing Guideline for Primary and …

Southwark Clinical Commissioning Group Lambeth Clinical Commissioning Group This document was developed by clinicians of NHS Lambeth CCG, NHS Southwark CCG, Departments of Dermatology and Pharmacy GSTFT & KCH.

  Guidelines, Prescribing, Prescribing guidelines

ACG Clinical Guideline: Evidenced Based Approach to the ...

The American Journal of GASTROENTEROLOGY VOLUME 108 | MAY 2013 www.amjgastro.com 680 Dellon et al. Table 1 . Summary and strengths of recommendations and evidence DIAGNOSIS Defi nition and causes of esophageal eosinophilia 1. Esophageal eosinophilia, the fi nding of eosinophils in the squamous epithelium of the esophagus, is abnormal and the underlying cause should be

  Guidelines, Based, Approach, Clinical, Evidenced, Acg clinical guideline, Evidenced based approach

CHILDHOOD ASTHMA and ANAESTHESIA ANAESTHESIA …

Sign up to receive ATOTW weekly - email worldanaesthesia@mac.com INTRODUCTION Asthma is a leading cause of morbidity in children throughout the world.

  Childhood, Anaesthesia, Asthma, Childhood asthma and anaesthesia anaesthesia